

MARKET REPORT



Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportunity

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu

Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression. According to WHO almost 350 million people worldwide were affected with depression in 2016. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression. The global anti-depressant drugs market was valued at \$13,755 million in 2016, and is estimated to reach \$15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023.

Key Benefits

This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.

Market estimations are based on comprehensive analysis of the key developments in the industry.

The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.

In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.

The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Anti-depressant Drugs Market Key Segments:

By Depression Disorder

Major Depressive Disorder

Obsessive-Compulsive Disorder

Generalized Anxiety Disorder

Panic Disorder

Others

By Product

Tricyclic Antidepressants

Selective Serotonin Reuptake Inhibitors

Serotonin-norepinephrine reuptake Inhibitors

Monoamine oxidase inhibitors

Serotonin antagonist and reuptake inhibitors

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Additional Details

Publisher : Allied Market Research

Reference : LI 182593

Number of Pages : 144

Report Format : PDF

Publisher Information :



Allied Market Research
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu [Report Updated: 01-01-2018]

- CHAPTER 1: INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Secondary Research1.4.2. Primary Research1.4.3. Analyst Tools and ModelsCHAPTER 2: EXECUTIVE SUMMARY2.1. CXO PERSPECTIVECHAPTER 3: MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top Investment Pockets3.2.2. Top Winning Strategies3.3. MARKET SHARE ANALYSIS3.4. PORTERS FIVE FORCES ANALYSIS3.5. MARKET DYNAMICS3.5.1. Drivers3.5.1.1. Increase in Prevalence of Depression3.5.1.2. Rise in Geriatric Population3.5.1.3. Increase in Awareness3.5.2. Restraints3.5.2.1. Non-Pharmacological Therapies Preferred Over Pharmacological Therapies3.5.2.2. Poor Efficacy and Safety Profiles3.5.2.3. Patent Expiry of Antidepressants leading to Weak Pipeline3.5.3. Opportunities3.5.3.1. Emergence of Novel Multimodal TherapiesCHAPTER 4: ANTI-DEPRESSANT DRUGS MARKET BY DEPRESSIVE DISORDER4.1. OVERVIEW4.1.1. Market Size and Forecast4.2. MAJOR DEPRESSIVE DISORDER4.2.1. Key Market Trends & Opportunities4.2.2. Market Size and Forecast4.2.3. Market Analysis, by Country4.3. OBSESSIVE-COMPULSIVE DISORDER4.3.1. Key Market Trends & Opportunities4.3.2. Market Size and Forecast4.3.3. Market Analysis, by Country4.4. GENERALIZED ANXIETY DISORDER4.4.1. Key Market Trends & Opportunities4.4.2. Market Size and Forecast4.4.3. Market Analysis, by Country4.5. PANIC DISORDER4.5.1. Key Market Trends & Opportunities4.5.2. Market Size and Forecast4.5.3. Market Analysis, by Country4.6. OTHERS4.6.1. Key Market Trends & Opportunities4.6.2. Market Size and Forecast4.6.3. Market Analysis, by CountryCHAPTER 5: ANTI-DEPRESSANT DRUGS MARKET BY PRODUCT TYPE5.1. OVERVIEW5.1.1. Market Size and Forecast5.2. TRICYCLIC ANTIDEPRESSANTS5.2.1. Market Size and Forecast5.2.2. Market Analysis, by Country5.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS5.3.1. Market Size and Forecast5.3.2. Market Analysis, by Country5.4. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS5.4.1. Market Size and Forecast5.4.2. Market Analysis, by Country5.5. MONOAMINE OXIDASE INHIBITORS5.5.1. Market Size and Forecast5.5.2. Market Analysis, by Country5.6. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS5.6.1. Market Size and Forecast5.6.2. Market Analysis, by Country5.7. OTHERS5.7.1. Market Size and Forecast5.7.2. Market Analysis, by CountryCHAPTER 6: ANTI-DEPRESSANT DRUGS MARKET BY GEOGRAPHY6.1. OVERVIEW6.1.1. Market Size and Forecast6.2. NORTH AMERICA6.2.1. Key Market Trends and Opportunities6.2.2. Market Size and Forecast, by Depressive Disorder6.2.3. Market Size and Forecast, by product type6.2.4. Market Analysis, by Country6.2.4.1. U.S. Market Size and Forecast, by Depressive Disorder6.2.4.2. U.S. Market Size and Forecast, by product type6.2.4.3. Canada Market Size and Forecast, by Depressive Disorder6.2.4.4. Canada Market Size and Forecast, by Product Type6.2.4.5. Mexico Market Size and Forecast, by Depressive Disorder6.2.4.6. Mexico Market Size and Forecast, by Product Type6.3. EUROPE6.3.1. Key Market Trends and Opportunities6.3.2. Market Size and Forecast, by Depressive Disorder6.3.3. Market Size and Forecast, by Product Type6.3.4. Market Analysis, by Country6.3.4.1. Germany Market Size and Forecast, by Depressive Disorder6.3.4.2. Germany Market Size and Forecast, by Product Type6.3.4.3. France Market Size and Forecast, by Depressive Disorder6.3.4.4. France Market Size and Forecast, by Product Type6.3.4.5. UK Market Size and Forecast, by Depressive Disorder6.3.4.6. UK Market Size and Forecast, by Product Type6.3.4.7. Italy Market Size and Forecast, by Depressive Disorder6.3.4.8. Italy Market Size and Forecast, by Product Type6.3.4.9. Spain Market Size and Forecast, by Depressive Disorder6.3.4.10. Spain

Market Size and Forecast, by Product Type6.3.4.11. Rest of Europe Market Size and Forecast, by Depressive Disorder6.3.4.12. Rest of Europe Market Size and Forecast, by Product Type6.4. ASIA-PACIFIC6.4.1. Key Market Trends and Opportunities6.4.2. Market Size and Forecast, by Depressive Disorder6.4.3. Market Size and Forecast, by Product Type6.4.4. Market Analysis, by Country6.4.4.1. Japan Market Size and Forecast, by Depressive Disorder6.4.4.2. Japan Market Size and Forecast, by Product Type6.4.4.3. China Market Size and Forecast, by Depressive Disorder6.4.4.4. China Market Size and Forecast, by Product Type6.4.4.5. Australia Market Size and Forecast, by Depressive Disorder6.4.4.6. Australia Market Size and Forecast, by Product Type6.4.4.7. India Market Size and Forecast, by Depressive Disorder6.4.4.8. India Market Size and Forecast, by Product Type6.4.4.9. South Korea Market Size and Forecast, by Depressive Disorder6.4.4.10. South Korea Market Size and Forecast, by Product Type6.4.4.11. Rest of Asia-Pacific Market Size and Forecast, by Depressive Disorder6.4.4.12. Rest of Asia-Pacific Market Size and Forecast, by Product Type6.5. LAMEA6.5.1. Key Market Trends and Opportunities6.5.2. Market Size and Forecast, by Depressive Disorder6.5.3. Market Size and Forecast, by Product Type6.5.4. Market Analysis, by Country6.5.4.1. Brazil Market Size and Forecast, by Depressive Disorder6.5.4.2. Brazil Market Size and Forecast, by Product Type6.5.4.3. Saudi Arabia Market Size and Forecast, by Depressive Disorder6.5.4.4. Saudi Arabia Market Size and Forecast, by Product Type6.5.4.5. South Africa Market Size and Forecast, by Depressive Disorder6.5.4.6. South Africa Market Size and Forecast, by Product Type6.5.4.7. Rest of LAMEA Market Size and Forecast, by Depressive Disorder6.5.4.8. Rest of LAMEA Market Size and Forecast, by Product TypeCHAPTER 7: COMPANY PROFILES7.1. ALKERMES PLC7.1.1. Company overview7.1.2. Company snapshot7.1.3. Business performance7.2. ALLERGAN PLC7.2.1. Company overview7.2.2. Company snapshot7.2.3. Operating business segments7.2.4. Business performance7.2.5. Key strategic moves and developments7.3. BRISTOL MYERS SQUIBB COMPANY7.3.1. Company overview7.3.2. Company snapshot7.3.3. Business performance7.4. ELI LILLY AND COMPANY7.4.1. Company overview7.4.2. Company snapshot7.4.3. Operating business segments7.4.4. Business performance7.5. GLAXOSMITHKLINE INC.7.5.1. Company overview7.5.2. Company snapshot7.5.3. Operating business segments7.5.4. Business performance7.6. H. LUNDBECK A/S7.6.1. Company overview7.6.2. Company snapshot7.6.3. Business performance7.6.4. Key strategic moves and developments7.7. MERCK INC.7.7.1. Company overview7.7.2. Company snapshot7.7.3. Operating business segments7.7.4. Business performance7.8. PFIZER INC.7.8.1. Company overview7.8.2. Company snapshot7.8.3. Operating business segments7.8.4. Business performance7.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.7.9.1. Company overview7.9.2. Company snapshot7.9.3. Operating business segments7.9.4. Business performance7.10. TAKEDA PHARMACEUTICAL INC.7.10.1. Company overview7.10.2. Company snapshot7.10.3. Business performance

List Of Tables in Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu [Report Updated: 01-01-2018]

TABLE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 02. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2016-2023 (\$MILLION)

TABLE 03. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2016-2023 (\$MILLION)

TABLE 04. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2016-2023 (\$MILLION)

TABLE 05. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR PANIC DISORDER, BY REGION, 2016-2023 (\$MILLION)

TABLE 06. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER DEPRESSIVE DISORDER, BY REGION, 2016-2023 (\$MILLION)

TABLE 07. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 08. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2016-2023 (\$MILLION)

TABLE 09. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2016-2023 (\$MILLION)

TABLE 10. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2016-2023 (\$MILLION)

TABLE 11. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2016-2023 (\$MILLION)

TABLE 12. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2016-2023 (\$MILLION)

TABLE 13. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER PRODUCT TYPE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 14. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY GEOGRAPHY, 2016-2023 (\$MILLION)

TABLE 15. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 16. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 17. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 18. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 19. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 20. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 21. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 22. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 23. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 24. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 25. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 26. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 27. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 28. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 29. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 30. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 31. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 32. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 33. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 34. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 35. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 36. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 37. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 38. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 39. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023

(\$MILLION)

TABLE 40. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 41. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 42. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 43. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 44. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 45. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 46. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 47. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 48. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 49. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 50. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 51. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 52. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 53. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 54. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 55. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 56. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 57. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 58. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 59. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 60. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 61. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 62. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 63. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 (\$MILLION)

TABLE 64. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 (\$MILLION)

TABLE 65. ALKERMES: COMPANY SNAPSHOT

TABLE 66. ALLERGAN: COMPANY SNAPSHOT

TABLE 67. ALLERGAN: OPERATING SEGMENTS

TABLE 68. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 69. LILLY: COMPANY SNAPSHOT

TABLE 70. LILLY: OPERATING SEGMENTS

TABLE 71. GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 72. GLAXOSMITHKLINE: OPERATING SEGMENTS

TABLE 73. LUNDBECK: COMPANY SNAPSHOT

TABLE 74. MERCK: COMPANY SNAPSHOT

TABLE 75. MERCK: OPERATING SEGMENTS

TABLE 76. PFIZER: COMPANY SNAPSHOT

TABLE 77. PFIZER: OPERATING SEGMENTS

TABLE 78. SAGE THERAPEUTICS: COMPANY SNAPSHOT

TABLE 79. TEVA: OPERATING SEGMENTS

TABLE 80. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT

List Of Figures, Charts and Diagrams in Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu [Report Updated: 01-01-2018]

FIGURE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 04. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 05. MARKET SHARE ANALYSIS, 2016

FIGURE 06. BARGAINING POWER OF BUYERS

FIGURE 07. BARGAINING POWER OF SUPPLIERS

FIGURE 08. THREAT OF NEW ENTRANTS

FIGURE 09. THREAT OF SUBSTITUTION

FIGURE 10. COMPETITIVE RIVALRY

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2016 & 2023 (%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2016 & 2023 (%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2016 & 2023 (%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER PRODUCT TYPE, BY COUNTRY, 2016 & 2023 (%)

FIGURE 22. ALKERMES: NET SALES, 2014-2016 (\$MILLION)

FIGURE 23. ALKERMES: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 24. ALKERMES: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 25. ALLERGAN: NET SALES, 2014-2016 (\$MILLION)

FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 27. BRISTOL MYERS SQUIBB: NET SALES, 2014-2016 (\$MILLION)

FIGURE 28. BRISTOL MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 29. LILLY: NET SALES, 2014-2016 (\$MILLION)

FIGURE 30. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 31. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 32. GLAXOSMITHKLINE: NET SALES, 2014-2016 (\$MILLION)

FIGURE 33. GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 34. GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 35. LUNDBECK: NET SALES, 2014-2016 (\$MILLION)

FIGURE 36. LUNDBECK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 37. MERCK: NET SALES, 2014-2016 (\$MILLION)

FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 39. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 40. PFIZER: NET SALES, 2014-2016 (\$MILLION)

FIGURE 41. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 42. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 43. TEVA: NET SALES, 2014-2016 (\$MILLION)

FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 45. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 46. TAKEDA PHARMACEUTICAL: NET SALES, 2014-2016 (\$MILLION)

FIGURE 47. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

How to Buy...

Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportu [Report Updated: 01-01-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/182157>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3840** | Single User Price
- \$5910** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.